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The clinical manifestations of alcohol dependence are not homogeneous. Many studies described both cognitive impairments 
and psychiatric disorders among people with Alcohol use disorder (AUD). However, AUD can be present without comorbid 
psychiatric disorders or severe cognitive deficits, namely, “pure alcoholics”. Until now, knowledge about effective treatments 
for this typology of AUD patients remains unknown. The aim of the present study was to assess two psychological methods of 
intervention: Cognitive-behavioral treatment (CBT) in the short format and the Motivational enhancement therapy (MET). We 
then opted to compare the efficacy of methods in treating AUD in both men and women pure alcoholics. We performed a controlled 
and randomized study consisting of 325 people affected by AUD (244 men, 81 women). 72.3% (n=235; 181 men 54 women) were 
excluded according to selection criteria. The major percentage of exclusion (38.7%; n=91; 63 men 28 women) regarded patients 
with comorbid psychiatric disorders. Only the 90 remaining test subjects (27.7% of the sample population; 63 men and 27 women) 
classified as pure alcoholics were eligible for this study. The test subjects were divided into two groups. One group underwent MET 
(n=47; 35 men and 12 women) and the other underwent CBT (n=43; 28 men and 15 women). We found a significant adherence 
to the treatment in the CBT group (19 men and 9 women) compared to the MET group (3 men and 1 woman). At the end of 
treatment, the dropout rates for the CBT and MET therapy groups were 34.9% and 91.5%, respectively. Moreover, we found no 
differences in the percentage of abstinent days between CBT and MET groups at three months (CBT: n=36; mean 91.40±15.34; 
MET: n=18; mean 93.90±11.95; t(52)= 0.605, p=0.550), at six months (CBT: N=30; mean 85.00±30.71; MET: n=9; mean 
87.78±33.08; t(37)=-0.234, p=0.820) and at twelve months from the beginning of treatment (CBT: n=28; mean 90.14±22.06; 
MET: n=4; mean 100±0; t(30)=-0.881, p=0.838). In conclusion, we disclose that CBT in the short format could be an effective 
treatment strategy for pure alcoholics without psychiatric disorders or severe cognitive deficits. Biomed Rev 2019;30:125-135 
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INTRODUCTION
Alcohol use disorder (AUD) is a clinically heterogeneous 
syndrome (1–4) for its physiological, behavioral, cognitive–
psychological and social multifactorial aspects (5–7). 
Alcohol use disorder can coexist with and/or contribute to 
several different psychiatric syndromes (8–11) and cognitive 
impairments	 (12–15).	 These	 factors	may	 influence	 the	
clinical expression of dependence, but also treatment-seeking 
behaviors and treatment outcomes (16–18). However, AUD 
can be present without comorbid (19,20) psychiatric disorders 
or	 severe	 cognitive	 deficits,	 namely,	pure alcoholics (21). 
Indeed, people drink to cope with stressful situations as 
economic problems, job issues and/or family troubles and 
could develop AUD also without co–occurring psychiatric 
disorders through DSM-5 (22–25). 
To	date,	some	studies	have	attempted	to	define	the	most	
effective treatments for dealing with AUD people low in 
psychopathology. In the MATCH Project Research Group 
(26), it was found that patients low in psychiatric severity had 
more abstinent days after 12-step facilitation treatment than 
after Cognitive Behavioral Therapy (CBT) and Motivational 
Enhancement	Therapy	 (MET).	This	 significant	matching	
effect	 for	 psychiatric	 severity	 observed	 in	 the	first	 year	 of	
post-treatment	was	not	confirmed	after	3	years	(27).	McLellan	
(28) found that patients with low psychiatric severity improved 
in every treatment program. Kadden (29) revealed that both 
coping skills training and interactional therapy were equally 
effective for patients lower in psychopathology. Moreover, 
patients more neuropsychologically impaired appeared to have 
better outcomes after interactional therapy (29). Nevertheless, 
treatments for AUD individuals without the confounding 
effects	 of	 comorbid	 psychopathology	 and	 cognitive	 deficit	
might be better explored. 
Actually, there is a strong interest to develop and validate 
evidence-based approaches for psychological treatment of 
AUD so that they can offer the best chances of success with a 
low cost. At present, evidence-based approaches are mainly 
based on the motivational interviewing (MI) (30, 31) and 
CBT (29, 31–35). The UKATT Research Team compared the 
treatment costs, consequences for public sector resources, 
and health outcomes of two brief treatments: social behavior 
and network therapy and motivational enhancement therapy, 
reporting	 highly	 significant	 reductions	 in	 drinking	 and	
associated problems and costs indifferently by treatments (36). 
The	data	confirmed	the	results	of	Project	MATCH	where	a	less	
intensive	and	costly	treatment	(MET)	did	offer	significantly	
equal outcomes compared to two more intensive and expensive 
treatments (CBT and TSF).
CBT models are among the most extensively used 
interventions for the treatment of AUD. Based primarily on 
Marlatt and Gordon’s (37,38) model of relapse prevention, 
these treatments usually includes strategies as: (1) identifying 
intrapersonal and interpersonal triggers for relapse, (2) coping-
skills training, (3) drug-refusal skills training, (4) functional 
analysis of substance use, and (5) increasing non-use-related 
activities. These models have been manualized (29, 39, 
40). Quite intensive and effective CBTs exist, also a briefer 
format tested with good results (41 ,42). The intervention 
aimed at maintaining total or partial abstinence by teaching 
and fostering self-monitoring and self-management abilities 
with minimum use of professional time. At one year, 47% of 
treatment-group participants continued to attend, compared 
with only 17% in the control groups (41, 42). 
Based on the considerations that i) CBT and MET are 
validated AUD treatments (43); ii) that MET is of more 
expensive than CBT (44, 45); iii) CBT exists in a short format 
(41, 42), the aim of the present study was to investigate and 
compare	the	efficacy	of	CBT	in	the	short	form	and	MET	in	a	
cohort of AUD men and women without comorbid psychiatric 
disorders	or	severe	cognitive	deficits	(“pure	alcoholics”).	
MATERIAL AND METHODS 
Participants and study design
A	randomized	controlled	clinical	trial	to	compare	the	efficacy	
of CBT and MET in pure alcoholics within a 2-years long 
follow-up study was conducted on 325 alcoholics patients 
(244 men and 81 women) but following the exclusion criteria 
described later the study was carried out on 90 pure alcoholics 
(63 men and 27 women) (Fig. 1 and Table 1). Participants 
received	a	two	weeks	long	detoxification	and	rehabilitation	
treatment in the “Latium Region Alcohol Referral Center” 
of Policlinico Umberto I, Sapienza University Hospital, in 
Rome, Italy. All participants received also pharmacological 
treatment (from 6 to 10 days of diazepam administration) 
to minimize withdrawal symptoms (46). This medication 
was progressively decreased during detox. Patient history of 
alcohol drinking behavior was based also on family history 
of alcohol dependence. Each patient’s smoking history was 
also assessed. Participants were included if they met criteria 
for a diagnosis of alcohol dependence according to the 
Diagnostic and Statistical Manual of Mental Disorders  (47) 
and if they had at least 7 days of alcohol abstinence. In order 
to recruit only pure alcoholics, participants were excluded if 
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Table 1. General characteristics of AUD people under treatment with Cognitive-Behavioural Treatment (CBT) and Motivational 
Interview (MI). Data are expressed as mean ± SEM. CAD: Cumulative Abstinence Duration; MMSE: Mini-Mental State Evaluation; 
WAIS-R: revised Wechsler Adult Intelligence Scale.
 
 
Table 1. General characteristics of AUD people under treatment with Cognitive-Behavioural Treatment (CBT) and 
Motivational Interview (MI). Data are expressed as mean ± SEM. CAD: Cumulative Abstinence Duration; MMSE: 
Mini-Mental State Evaluation; WAIS-R: revised Wechsler Adult Intelligence Scale. 
Variables 
CBT MI 
Men (n=28) Women (n=15) Men (n=35) Women (n=12) 
Age 46.82 (2.06) 50.40 (2.10) 46.26 (1.69) 46.17 (2.52) 
Educational Level 
(1 Low 4 Top) 
2.75 (.15) 2.93 (.15) 2.51 (.10) 3.08 (.23) 
Age of onset alcohol problems 30.93 (2.05) 33.33 (3.26) 27.09 (1.66) 31.33 (4.23) 
Years of consumption 13.81 (1.75) 15.67 (2.65) 18.34 (1.69) 11.33 (3.37) 
Alcohol Preference (%):     
Wine 52.6% 42.5% 46.4% 52.1% 
Beer 31.5% 32.3% 26.5% 29.1% 
Spirit 14.5% 26% 25.6% 13.6% 
Abstinence days before the test 
(CAD) 
5.39 (.68) 5.07 (.71) 6.01 (.50) 4.75 (.65) 
Alcohol units per day  
(last 3 months) 
12.51 (1.45) 12.21 (1.92) 14.72 (2.26) 9.40 (1.63) 
Previous use of psychoactive substances 
(%) 14.3% 33.3% 22.9% 16.7% 
Smoking 
(daily number of cigarettes) 
17.89 (2.39) 11.33 (3.34) 21.37 (2.49) 15.02 (3.74) 
Drug use for alcohol treatment:  
Naltrexone 35.9 23.3 33.50 25.14 
Nalmefene 22.9 18.6 20.40 22.45 
Acamprosate 41.2 58.1 46.10 52.51 
MMSE (raw score) 16.18 (.25) 16.27 (.23) 15.77 (.24) 15.92 (.50) 
WAIS Vocabulary (raw score) 44.11 (2.60) 42.56 (3.11) 40.14 (2.49) 39.00 (4.25) 
SCL-90:     
 Somatization .37 (.06) .61 (.15) .49 (.06) .68 (.14) 
 Obsessive-Compulsive .68 (.09) .74 (.10) .74 (.07) .55 (.10) 
 Interpersonal Sensitivity .36 (.07) .46 (.10) .47 (.08) .68 (.16) 
 Depression .59 (.08) .67 (.10) .61 (.08) .82 (.12) 
 Anxiety .42 (.06) .63 (.10) .55 (.07) .62 (.10) 
 Hostility .24 (.04) .37 (.08) .43 (.07) .32 (.08) 
 Phobic Anxiety .11 (.04) .20 (.10) .12 (.03) .19 (.08) 
 Paranoid Ideation .49 (.08) .61 (.17) .56 (.07) .74 (.17) 
 Psychoticism .26 (.05) .37 (.07) .43 (.07) .51 (.12) 
 Global Severity Index .44 (.05) .55 (.08) .53 (.05) .61 (.08) 
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they scored above 1 on the Symptom Checklist-90 (SCL-90) 
test (48) referring a psychiatric disorder or met the criteria of 
a cognitive impairment assessed by using Mini-Mental State 
Examination (MMSE) (49) and Vocabulary Wechsler Adult 
Intelligence Scale (WAIS IV) tests (50). Patients were also 
excluded if they: i) had evident psychopathological conditions 
at the psychiatrist evaluation; ii) had history of other substance 
abuse (as cocaine, opioids, amphetamine, other recreational 
drugs, anxiolytics, euphoriants, antipsychotics, barbiturates, 
benzodiazepines, antidepressants, hallucinogens – data 
based on patients urine toxicology), except than nicotine or 
cannabis, according to DSM-5 criteria in the last 90 days (6 
months for opiate abuse) or based on urine drug screening; 
iii) had unstable medical conditions (eg, serum liver enzyme 
levels 3 times the limits of normal or hypertension); iv) 
had history of head injury, loss of consciousness, history of 
organic mental disorder, seizure disorder or central nervous 
system diseases and no sign of hypertension at the time of 
recruitment; v) could not communicate in Italian; vi) zero 
blood alcohol levels during testing. Participants were asked 
to complete the screening and assessment tests after the 
disappearing of the withdrawal symptoms (according to a set 
of	 specified	withdrawal	 symptoms,	 such	 as	 elevated	blood	
pressure, tachycardia, tremor, sweating, etc.), and after the 
end of the pharmacological treatment. 235 participants (181 
men and 54 women) were excluded according to exclusion/
inclusion criteria just described. Other participants (n=42, 
34 men, 8 women) potentially eligible for the inclusion in 
the study were excluded because they declined to participate 
or for other psychosocial treatments or for the impossibility 
to attend the sessions. Following participants selection, the 
number of eligible pure alcoholics were 90 (63 men and 27 
women). One group received MET (n=47; 35 men and 12 
women) and the other group received CBT (n= 43; 28 men 
15 women). Both treatments were followed by well-trained 
alcoholism treatment specialists. The study was approved by 
the hospital’s IRB committee and an informed consent was 
signed by each participant. Blood alcohol levels were measured 
in all participants by using Alcoscan AL7000.
PROCEDURE 
MET and CBT Description 
Motivational Enhancement Therapy consists of a 3-sessions 
client-centered intervention, designed to enhance patient motiva-
tion for behavioral change in addictive behavior. It focuses on 
exploring and resolving ambivalence by increasing intrinsic mo-
tivation to change (26,31). The objectives of the clinical sessions 
were respectively: 1) to enhance internal motivation to change; 
2) to reinforce this motivation; 3) to develop a plan to achieve 
the change. Motivational Enhancement Therapy has been shown 
to be effective in improving substance abuse recovery outcomes 
by itself, as well as in combination with other treatments (43). It 
has been particularly effective in pre-treatment work to engage 
and motivate clients for other treatment modalities (43). The 
duration of each session was about 60 minutes. 
Cognitive Behavioral Therapy consists of a 5-sessions inter-
vention focused on changing of addictive behavior through the 
application of combined cognitive and behavioral interventions 
(29, 41, 42). The goals of the clinical sessions were respec-
tively:	1)	identifying	specific	high-risk	situations	in	the	past	
and in the present; 2) enhancing the patients’ skills for coping 
with	those	situations	and	increasing	the	patients’	self-efficacy;	
3) eliminating myths regarding alcohol’s effects; 4) managing 
lapses and restructuring the patients’ perceptions of the relapse 
process; 5) strengthening the ability of recognizing and cop-
ing with the situations at high risk of drinking. Compared to 
treatment program used in previous studies (41, 42), strate-
gies for the management of relapses were added (33). Global 
strategies were used included balancing the patients’ lifestyle 
and helping him or her to develop positive addictions, using 
stimulus control techniques and urge-management techniques, 
and developing relapse road maps. The duration of each ses-
sion is about 60 minutes. Medical follow up every month till 
one year were conducted including blood alcohol checking. 
Participants received the psychosocial intervention in the 
first	three	months.	Psychological	follow	up	at	third,	sixth	and	
twelfth months after the end of the treatment was conducted.
Both CBT and MET groups were led by well-trained 
therapists who participated in several alcohol treatments (CBT 
or MET) trainings and with at least 3 years of experience. 
DATA ANALYSIS
Preliminary analyses were carried out comparing (by chi-
square or ANOVA) enrolled patients assigned to the two groups 
at the baseline assessment to evaluate the randomization 
success with gender as covariate factor. To evaluate the 
adherence to the treatment Kaplan Meyer survival curves were 
used adjusted for gender. Independent sample T-test was used 
to compare the effect of the CBT on alcoholic variables at 
baseline, three, six months and one year. All statistical analyses 
were performed by using SPSS software (version 23; IBM 
SPSS Statistics, Chicago, IL). 
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RESULTS 
Sample characteristics and baseline differences
Patients enrolled in the study were 325, of these 72.3% 
(n=235) were excluded according to exclusion/inclusion 
criteria. The major percentage of exclusion (38.72%; n=91) 
regarded patients with comorbid psychiatric disorders, 17.02% 
(n=40) had cognitive impairments and 16.60% (n=39) had 
both cognitive impairments and psychiatric disorders. Low 
percentage of exclusion regarding patients with organic 
problems (1.28%; n=3), polysubstance abuse (2.98%; n=7), 
patients who did not speak Italian very well to follow the 
clinical sessions (0.43%; n=1) and patients that did not reached 
7 continuous days of abstinence (15.11%; n=12). Moreover, 
some patients were excluded because they were enrolled in 
other psychosocial treatment(s), for the impossibility to attend 
sessions or because they declined to participate (17.87%: 
n=42).	The	final	number	of	eligible	patients	was	90	(27.7%).	
They were assigned to the CBT or to the MET group. The 
final	sample	was	composed	of	43	patients	included	into	the	
CBT group (men=28, women=15) and 47 into the MET group 
(men=35,	women=12).	The	Figure	1	shows	the	flow	diagram	
of this study. 
Approximately 70% (n=63) of the patients were men 
(CBT: n=28 - 65.1%; MET: n=35 - 74.5%), and their mean 
age was 47.11±9.8 years. The mean age at the onset of alcohol 
problems was 29.88±11.33 years (men: 28.76±10.27; women: 
32.44±13.32). The patient group reported an average of 
15.59±10.12 years of problem drinking (men: 16.41±9.74; 
women: 13.74±10.90) and an average of 13.69±10.28 
drinks (men: 14.89±11.33; women: 10.96±6.73) per day 
during three months prior to admission to the treatment 
unit. Randomization successfully matched participants since 
there were no differences in baseline socio-demographic 
characteristics included gender, alcohol variables, and 
psychological variables between the two groups. Means and 
standard deviations of the demographic, alcoholic variables 
and screening measures divided for gender are reported in 
Table 1. Moreover, the patients were compared for gender on 
all measures described above. 
CBT versus MET: Efficacy of the Treatment  
on Adherence 
Kaplan-Meier survival curves were conducted to assess the 
differences in adherence to the treatment between the two 
groups	and	stratified	for	gender.	
Results	 indicate	 a	 significant	 globally	 difference	 in	 the	
adherence to the treatment adjusted for gender (Log-rank 
score: 23.50(1), p<0.001; Breslow: 14.32(1), p<0.001; Tarone 
Ware: 18.80(1), p p<0.001), as shown in Figure. 2. 
Figure 2. Dropout expressed as % of AUD people under 










The Kaplan–Meier proportion of patients remaining in 
treatment during the years was greater for the CBT group, 
than the MET group, as well as at 45 days, three, six, and 
twelve months. By the end of the year, 65.1% (n=28) of CBT 
patients remained in treatment compared to 8.5% (n=4) of 
MET patients. At 45 days, three, six and twelve months, the 
dropout rates in MET was 49% (n=24); 61.7% (n=29), 80.9% 
(n=38) and 91.5% (n=43) and in CBT it was 7% (n=3), 16.3% 
(n=7), 30.2% (n=13), and 34.9% (n=15), respectively. The 
highest	percentage	of	dropout	happened	in	the	first	45	days	of	
treatment, with a greater tendency in MET group. 
In particular, in the CBT group, men dropping out after 
45 days were 7.14% and after 1 year 32.14%; while women 
dropping out after 45 days were 6.67% and after 1 year 40%.
In the MET group, men dropping out after 45 days were 
57.14% and after 1 year 91.43%; while women dropping out 
after 45 days were 33.3% and after 1 year 91.7%.
CBT versus MET: Efficacy of the treatment  
on abstinence
Independent sample T-test considering the CBT and the MET 
groups as factors and the dependent variables were carried out 
on the percentage of abstinence days in the treatment period 
and the mean of alcoholic unit per day drunk in the treatment 
period. The differences on alcoholic variables were considered 
at	the	baseline	(after	the	detoxification),	at	the	first	follow	up	
(after three months), at the second follow up (after six months) 
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and at the last follow up (after one year). Patients enrolled in 
both the CBT and in the MET did not refer differences at the 
baseline in the percentage of abstinence days (CBT: n=43; mean 
96.83±7.75; MET: n=47; mean 92.23±15.72; t(68)=1.787, 
p=0.080) and total alcohol consumption per day (CBT: n=43; 
mean 3.63±9.02; MET: n=47; mean 11.83±23.75; t(68)=-
1.606, p=0.120). Moreover, no differences between the two 
groups were found in the other alcoholic variables. Particularly, 
at three months the percentage of abstinent day (CBT: n=36; 
mean 91.40±15.34; MET: n=18; mean 93.90±11.95; t(52)=-
0.605, p=0.550) and total alcohol consumption per day (CBT: 
n=36; mean 25.67±49.52; MET: n=18; mean 32.83±64.04; 
t(52)=-0.454, p=0.650) did not differ between groups at six 
months (the percentage of abstinent day (CBT: N=30; mean 
85.00±30.71; MET: n=9; mean 87.78±33.08; t(37)=-0.234, 
p=0.820) and total alcohol consumption per day (CBT: n=30; 
mean 53.07±113.73; MET: n=9; mean 105.22±245.49; t(37)= 
-0.891, p=0.380) were unaffected as well. After one year no 
differences were found in the two groups in the percentage 
of abstinence days (CBT: n=28; mean 90.14±22.06; MET: 
n=4; mean 100±0; t(30)=-0.881, p=0.838) and total alcohol 
consumption per day (CBT: n=28; mean 40.90±93.25; MET: 
n=4; mean 0±0; t(30)=0.865, p=0.380) but only four patients 
of the control group were totally abstinent. A linear regression 
was conducted to assess if the abstinence was predicted by 
the number of sessions attended in the different stages of the 
studies. Results showed that the abstinence was not predicted 
by the number of sessions at three months (F(1,52)=1.481; 
p=0.229), six months (F(1,30)=3.069; p=0.090) and one year 
(F(1,28)= 0.034; p=0.855). 
DISCUSSION
We tested the effectiveness of the CBT versus MET in patients 
without concomitant psychiatric disorders and/or cognitive 
impairments. Patients attending CBT remained in treatment 
significantly	more	than	the	MET	group.	Cessation	of	therapy	
has often been mentioned as a problem closely related to 
relapse (51). Although relapsing rate may have various rates, 
the relapse may range from 80% to 90%, with 50-60% of 
alcohol-dependent	individuals	relapsing	within	the	first	three	
months of treatment (37, 52–54). Therefore, we considered 
the	adherence	to	the	treatment	to	evaluate	its	efficacy.	Results	
demonstrated	a	significant	retention	in	treatment	in	the	group	
undergoing CBT more than the MET group. The survival 
curves	of	the	two	groups	are	significantly	different.	The	CBT	
group	lost	few	patients	within	the	first	three	critical	months	of	
treatment (n=7; 16.3%), and after six months of treatment the 
course become stable. The MET group lost immediately many 
patients (n=29; 61.7%) and gradually so many others in the 
course of treatment. At the end of treatment, 65.1% (n=28) of 
the CBT group remained in treatment (dropout rates=34.9%) 
and only 8.5% (n=4) of the MET group (dropout rates=91.5%). 
The CBT seems to have a stronger power to maintain patients 
in	treatment	mainly	during	the	first	three	months	when	dropout	
is known to occur much more frequently (37). In fact, in our 
study it was observed that a considerable number of patients 
in	the	MET	group	left	before	the	first	follow	up	if	compared 
to the CBT group drop out. These results are consistent with 
a previous study conducted with alcoholic patients admitted 
to the program of the Sapienza University of Rome in which 
it was found that after one year 47% of the patients treated 
with CBT continued to attend compared with only 17% of 
the MET group which received standard medical treatment 
(42). Moreover, we found no differences between CBT and 
MET groups on percentage of abstinent days and on the daily 
consumption at three, six, twelve months from the beginning 
of treatment but only few patients remaining in the MET 
treatment. In conclusion, our results showed a strong impact 
of	CBT	 on	 patient	 retention	 in	 treatment	 confirming	 its	
effectiveness in the treatment of alcohol use disorders (43,55) 
also with AUD patients without psychiatric disorders and 
cognitive	deficits.	
Although many social, environmental, physiological, 
genetic and neurobiological factors have been demonstrated to 
contribute to the sex difference in response to alcohol intake, 
as well as the development of alcoholic complications (56, 57), 
our research did not reveal any gender differences in MET and/
or CBT responses. Only few studies have examined gender 
differences in the effectiveness of alcohol treatment without 
showing clear gender differences in treatment responses (58, 
59)	and	the	results	of	our	study	seem	to	confirm	this	trend.	
However, the issue of drinking abuse in women is quite 
important since women are more sensitive compared to men 
to the damage induced by alcohol (60, 61) and because women 
who drink during pregnancy may elicit a variety of negative 
effects to the fetus named Fetal Alcohol Spectrum Disorders 
(FASD) (62–73) as also shown in animal model (65, 70, 73–
75). The present study also discloses the limits of self-reporting 
on alcohol consumption to evaluate change in drinking because 
the amount of alcohol consumption reported may be under 
or overestimated (76). Further, the considerations on gender 
differences on the effectiveness of treatment should be taken 
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with care since men and women were not well balanced for 
two treatment groups.	Considering	the	strengths,	a	firm	point	
of the design of this study is the possibility to compare two 
interventions that in literature were considered both effective 
in AUD treatment. Indeed, CBT was not compared to a 
waiting list or a pharmacological treatment. It can be argued 
that CBT may have a stronger effect in retaining patients in 
treatment and in enhancing the ability to manage critical 
situations related to alcohol abuse. Therefore, as the samples 
were homogeneous and without psychiatric conditions, we 
can assert that CBT is responsible for the effects on alcohol 
consumption improvement in coping and management 
skills.	CBT	allows	achieving	significant	results	(adherence	
to treatment and abstinence from alcohol) by using a relative 
few sessions in one year of treatment and with minimum use 
of professional time. The present study is consistent also 
with a recent meta-analysis showing that a higher number of 
CBT/MET sessions was associated negatively with alcohol 
outcome (77). 
CONCLUSIONS
In conclusion, pure alcoholics having only dependence from 
alcohol but without other mental disorders or severe cognitive 
deficits	are	supposed	to	possess	sufficient	resources	to	deal	
with alcohol addiction without psychosocial treatment. 
However, the results of our study show that without the 
suitable	clinical	treatment,	it	is	very	difficult	to	quit	drinking	
and coping with the alcohol-related problems. An early and 
short cognitive-behavioral intervention is strongly suggested 
to prevent physical and/or mental health complications due to 
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